Galapagos NV (GLPG): Price and Financial Metrics

Galapagos NV (GLPG)

Today's Latest Price: $195.98 USD

3.70 (-1.85%)

Updated Jun 4 6:55pm

Add GLPG to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

GLPG Stock Summary

  • With a year-over-year growth in debt of 21,864.54%, Galapagos Nv's debt growth rate surpasses 99.54% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Galapagos Nv is reporting a growth rate of -224.82%; that's higher than just 7.57% of US stocks.
  • As for revenue growth, note that GLPG's revenue has grown 1,371.61% over the past 12 months; that beats the revenue growth of 99.4% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Galapagos Nv, a group of peers worth examining would be TLC, VNE, ERYP, ACIU, and AFMD.
  • Visit GLPG's SEC page to see the company's official filings. To visit the company's web site, go to
GLPG Daily Price Range
GLPG 52-Week Price Range

GLPG Stock Price Chart More Charts

GLPG Price/Volume Stats

Current price $195.98 52-week high $274.03
Prev. close $199.68 52-week low $112.00
Day low $195.64 Volume 97,100
Day high $203.46 Avg. volume 174,135
50-day MA $207.00 Dividend yield N/A
200-day MA $196.42 Market Cap 12.70B

Galapagos NV (GLPG) Company Bio

Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines in areas such as cystic fibrosis, inflammation, and other indications. The company was founded in 1999 and is Mechelen, Belgium.

GLPG Latest News Stream

Event/TimeNews Detail
Loading, please wait...

GLPG Latest Social Stream

Loading social stream, please wait...

View Full GLPG Social Stream

Latest GLPG News From Around the Web

Below are the latest news stories about Galapagos Nv that investors may wish to consider to help them evaluate GLPG as an investment opportunity.

Galapagos shares rise on Phase 3 studies of arthritis drug it's making with Gilead

Galapagos rose nearly 3% in early Amsterdam trade as Phase 3 studies of drug it's making with Gilead Sciences showed "sustained efficacy and a consistent safety profile" in treating moderately to severely active rheumatoid arthritis. The companies said they will be presenting the data on filgotinib at the European League Against Rheumatism's European E-Congress of Rheumatology 2020.

Yahoo | June 4, 2020

Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced Week 52 results from the Phase 3 FINCH 1 and FINCH 3 studies of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately to severely active rheumatoid arthritis (RA). The data demonstrate sustained efficacy and a consistent safety profile with up to 52 weeks of filgotinib treatment across RA patient populations. The new data are among 15 abstracts on filgotinib in RA that will be presented at the European League Against Rheumatism, EULAR, European E-Congress of Rheumatology 2020.

Yahoo | June 4, 2020

The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Th...

Benzinga | May 21, 2020

Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib Results

In a phase 2b/3 study in ulcerative colitis, the drug candidate met its goals, but with results that didn't appear better than those of a potential competitor.

Yahoo | May 21, 2020

Gilead and Galapagos Score Positive Topline Results For Ulcerative Colitis Trial

Gilead Sciences (GILD) and Galapagos NV (GLPG) have announced positive topline results from a Phase 2b/3 trial evaluating the efficacy and safety of the selective JAK1 inhibitor filgotinib in 1,348 patients with moderately to severely active ulcerative colitis (UC).UC is a chronic, idiopathic inflammatory disease affecting the colon and often involves periods of remission interspersed with periods of active disease.Filgotinib 200 mg achieved all primary endpoints in the placebo-controlled trial, inducing clinical remission at Week 10 and maintaining clinical remission at Week 58 in a significantly higher proportion of patients compared with placebo.However Filgotinib 100 mg did not achieve statistically significant clinical remission at Week 10.Rates of adverse events were low and compa...

Yahoo | May 21, 2020

Read More 'GLPG' Stories Here

GLPG Price Returns

1-mo -11.15%
3-mo -5.55%
6-mo -8.21%
1-year 68.80%
3-year 146.64%
5-year 276.38%
YTD -5.25%
2019 125.45%
2018 -2.15%
2017 46.07%
2016 2.08%
2015 239.71%

Continue Researching GLPG

Want to see what other sources are saying about Galapagos Nv's financials and stock price? Try the links below:

Galapagos Nv (GLPG) Stock Price | Nasdaq
Galapagos Nv (GLPG) Stock Quote, History and News - Yahoo Finance
Galapagos Nv (GLPG) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1701 seconds.